Thomas Aparicio

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.3K citations

Medicine, Oncology, Surgery +17

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

Bruno Chauffert, F. Mornex, F. Bonnetain et al. · Annals of Oncology · 2008 · 694 citations

Medicine, Oncology, Radiation Oncology +15

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

Emmanuel Mitry, Éric Baudin, Michel Ducreux et al. · British Journal of Cancer · 1999 · 495 citations · Full text

Medicine, Oncology, Pharmacology +12

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Thierry André, David Tougeron, Guillaume Piessen et al. · Journal of Clinical Oncology · 2022 · 379 citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14